{
    "clinical_study": {
        "@rank": "67250", 
        "arm_group": [
            {
                "arm_group_label": "Chemo plus Autologous Transplantation", 
                "arm_group_type": "Experimental", 
                "description": "Bendamustine 200 mg/ m2/ day on Days - 24 and Day - 23 followed by a short break of 10 - 14 days, followed by Melphalan, Carmustine, Etoposide, Cytarabine (BEAM) and alemtuzumab, plus rituximab for all b-cell malignancies, followed by autologous transplant"
            }, 
            {
                "arm_group_label": "Chemo plus Allogeneic Transplantion", 
                "arm_group_type": "Experimental", 
                "description": "Bendamustine 200 mg/ m2/ day on Days - 24 and Day - 23 followed by a short break of 10 - 14 days, followed by Melphalan, Carmustine, Etoposide, Cytarabine (BEAM) and alemtuzumab, plus rituximab for all b-cell malignancies, followed by allogeneic transplant"
            }
        ], 
        "brief_summary": {
            "textblock": "This clinical trial is for men and women with whose lymphoma (non-Hodgkin or Hodgkin) did\n      not respond to treatment or has returned after responding to previous therapy, and who are\n      in need of a stem cell transplant.\n\n      The purpose of this study is to test the safety and effectiveness of giving the drug\n      Bendamustine, followed by high dose chemotherapy, within two weeks prior to a stem cell\n      transplant for lymphoma that has not achieved a complete response to salvage (treatment used\n      for relapsed disease) chemotherapy."
        }, 
        "brief_title": "Lymphoma Bridge Transplant Study", 
        "completion_date": {
            "#text": "February 2019", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Hodgkin's Lymphoma", 
            "Non-Hodgkin's Lymphoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hodgkin Disease", 
                "Lymphoma", 
                "Lymphoma, Non-Hodgkin"
            ]
        }, 
        "detailed_description": {
            "textblock": "Subjects with Hodgkin's or Non-Hodgkin's lymphoma that did not respond to treatment or have\n      disease that has returned after responding to previous treatment, and are in need of a stem\n      cell transplant will be eligible for this pilot study. Thirty subjects will be enrolled,\n      with 15 subjects assigned to the autologous transplant cohort (according to disease status\n      and eligibility) and 15 subjects to the allogeneic transplant cohort (according to diseases\n      status and eligibility).\n\n      Subjects will undergo the following a number of screening procedures to determine\n      eligibility. All eligible subjects will receive bendamustine at a dose of 200 mg/ m2/ day\n      for two days on Days - 24 and Day - 23 followed by a short break of 10 - 14 days. Subjects\n      will then receive the conditioning regimen, BEAM (carmustine, etoposide, cytarabine\n      arabinoside, and Melphalan) and alemtuzumab for 6 days (Day -6 to Day -1) followed by an\n      autologous or allogeneic transplant.\n\n      Subjects with pathological confirmed B-cell malignancies will also receive rituximab 375\n      mg/m2 on Days + 1 and +8 post-transplant. Subjects with T-cell lymphoma will be enrolled in\n      the study but will not receive rituximab.\n\n      After the transplantation all subjects will receive medication to prevent graft vs host\n      disease and supportive care to prevent infections. To speed up the recovery of stem cells,\n      subjects will receive post-transplant filgrastim (G-CSF).\n\n      After discharge from the hospital, subjects will be seen regularly in the clinic for an exam\n      and assessments. All these tests are considered standard of care."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  must have histologically or cytologically confirmed relapsed or primary refractory\n             lymphoma (including Hodgkin's Lymphoma) staged with PET scan to have\n\n               -  Allogeneic arm:\n\n                    -  Progressive disease or\n\n                    -  No response to salvage therapy or\n\n                    -  Partial response to salvage therapy defined as > 50% reduction in\n                       bidirectional area of masses but SUV remains \u22658 in at least some PET avid\n                       areas\n\n               -  Autologous arm:\n\n                    -  Partial response of >50% reduction in bidirectional area of masses and SUV\n                       reduction to <8 in PET avid areas Subjects must have evaluable disease.\n\n          -  Subjects must have received at least one induction therapy and one line of salvage\n             therapy that each incorporate at least two drugs that are standard of care for\n             lymphoma (such as alkylating agents, anthracyclines, topo II inhibitors, vinca\n             alkaloids, corticosteroids, if the disease was PET avid)\n\n          -  Age >18 years.\n\n          -  KPS (Karnofsky Performance Score) \u2265 60%\n\n          -  For autologous transplants: Subjects must have an adequate number of CD34+ stem cells\n             collected to allow for transplantation. This number is defined as \u2265 2x106 CD34+ cells\n             / kg body weight. If not previously collected and stored, the subject must be willing\n             to undergo stem cell mobilization and collection as per standard practice. If\n             sufficient cells cannot be collected, subjects will be offered the option to proceed\n             with the allogeneic arm of the study.\n\n          -  Male and female subjects must use an effective contraceptive method during the study\n             and for a minimum of 6 months after study treatment. Female subjects of childbearing\n             potential must have a negative serum pregnancy test within 2 weeks prior to\n             enrollment.\n\n          -  Ability to understand and the willingness to sign a written informed consent\n             document.\n\n        Exclusion Criteria:\n\n          -  Known to be positive for HIV\n\n          -  Subjects may not be receiving any other investigational agents (defined as non\n             FDA-approved agents) at the time of initiating bendamustine regimen.\n\n          -  Women who are pregnant or breast feeding. Women of childbearing age must use adequate\n             contraception and have a negative pregnancy test.\n\n          -  The risks to an unborn fetus or potential risks in nursing infants are unknown.\n\n          -  History of allergic reactions attributed to compounds of similar chemical or biologic\n             composition to any medications listed in the protocol.\n\n          -  Subject with severely decreased Left Ventricular Ejection Fraction (LVEF) or severely\n             impaired pulmonary function tests (PFT's)\n\n          -  Uncontrolled illness including, but not limited to, ongoing or active infection,\n             symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia,\n             or psychiatric illness/social situations that would limit compliance with study\n             requirements."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 6, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02059239", 
            "org_study_id": "1208012875"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Chemo plus Autologous Transplantation", 
                    "Chemo plus Allogeneic Transplantion"
                ], 
                "description": "Days - 24 and Day - 23 followed by a short break of 10 - 14 days.", 
                "intervention_name": "Bendamustine", 
                "intervention_type": "Drug", 
                "other_name": "Treanda"
            }, 
            {
                "arm_group_label": [
                    "Chemo plus Autologous Transplantation", 
                    "Chemo plus Allogeneic Transplantion"
                ], 
                "description": "300 mg/m2 on Day -6", 
                "intervention_name": "Carmustine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Chemo plus Autologous Transplantation", 
                    "Chemo plus Allogeneic Transplantion"
                ], 
                "description": "100 mg/m2 on days -5 to -2", 
                "intervention_name": "Etoposide", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Chemo plus Autologous Transplantation", 
                    "Chemo plus Allogeneic Transplantion"
                ], 
                "description": "140mg/m2 on Day -1", 
                "intervention_name": "Melphalan", 
                "intervention_type": "Drug", 
                "other_name": "Alkeran"
            }, 
            {
                "arm_group_label": [
                    "Chemo plus Autologous Transplantation", 
                    "Chemo plus Allogeneic Transplantion"
                ], 
                "description": "200 mg/m2 on days -5 to -2", 
                "intervention_name": "Cytarabine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Chemo plus Autologous Transplantation", 
                    "Chemo plus Allogeneic Transplantion"
                ], 
                "description": "20 mg/m2 days -6 to -2 for UNRELATED donors, and 20 mg/m2 days -4 to -2 for RELATED donors", 
                "intervention_name": "Alemtuzumab", 
                "intervention_type": "Drug", 
                "other_name": "Campath"
            }, 
            {
                "arm_group_label": "Chemo plus Autologous Transplantation", 
                "intervention_name": "Autologous Stem Cell Transplantation", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Chemo plus Allogeneic Transplantion", 
                "intervention_name": "Allogeneic Stem Cell Transplantation", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": [
                    "Chemo plus Autologous Transplantation", 
                    "Chemo plus Allogeneic Transplantion"
                ], 
                "description": "Only to be administered in subjects with B-cell malignancies. Dose is 375 mg/m2 on Days 1 and 8 post-transplant", 
                "intervention_name": "Rituximab", 
                "intervention_type": "Drug", 
                "other_name": "Rituxan"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Carmustine", 
                "Melphalan", 
                "Etoposide phosphate", 
                "Bendamustine", 
                "Alemtuzumab", 
                "Rituximab", 
                "Cytarabine", 
                "Etoposide", 
                "Campath 1G"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "NHL", 
            "HL", 
            "Lymphoma"
        ], 
        "lastchanged_date": "February 6, 2014", 
        "location": {
            "contact": {
                "email": "jdg2002@med.cornell.edu", 
                "last_name": "June Greenberg, RN", 
                "phone": "212-746-2651"
            }, 
            "contact_backup": {
                "email": "jer9005@med.cornell.edu", 
                "last_name": "Jessy Ryan, NP", 
                "phone": "212-746-2646"
            }, 
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10065"
                }, 
                "name": "Weill Cornell Medical College"
            }, 
            "investigator": {
                "last_name": "Tsiporah Shore, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Pilot Study of a Sequential Regimen of Intensive Chemotherapy Followed by Autologous or Allogeneic Transplantation for Refractory Lymphoma (Non-Hodgkin's and Hodgkin's)", 
        "overall_contact": {
            "email": "jdg2002@med.cornell.edu", 
            "last_name": "June Greenberg, RN", 
            "phone": "212-746-2651"
        }, 
        "overall_official": {
            "affiliation": "Weill Medical College of Cornell University", 
            "last_name": "Tsiporah Shore, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Evaluate the number of subjects who proceed to transplant following bendamustine treatment. Subjects must have neutrophil count of 500/mm3 and platelet count of 20,000 without platelet support for one week following bendmustine treatment. Subjects will then move on to transplant.", 
            "measure": "Number of patients who recover from bendamustine and proceed to transplant", 
            "safety_issue": "Yes", 
            "time_frame": "estimation of 14 days per patient; two years for all patients enrolled on the study"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02059239"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Evaluate the number of patients who demonstrate complete, partial, no response, or progression at day 100 and day 365 of the study", 
                "measure": "Number of patients who exhibit a response after bendamustine and after transplant", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "Evaluate the survival rate of subjects post initiation of bendamustine and post-transplant, as well as overall survival rates", 
                "measure": "Survival of subjects at 100 days, 1 year after treatment", 
                "safety_issue": "No", 
                "time_frame": "5 years"
            }, 
            {
                "description": "Evaluate the number of deaths due to treatment within the first 100 days", 
                "measure": "Transplant-related mortality rate", 
                "safety_issue": "No", 
                "time_frame": "estimation of 100 days per patient; 2 years for all patients enrolled on the study"
            }
        ], 
        "source": "Weill Medical College of Cornell University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Weill Medical College of Cornell University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}